Aarkstore Aarkstore || Central Nervous System Disorders Therapeutics Market

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) November 30, 2011 -- Aarkstore.com announces, a new market research report is available in its vast collection:

Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
http://www.aarkstore.com/reports/Central-Nervous-System-Disorders-Therapeutics-Market-to-2017-Multiple-Sclerosis-Major-Depressive-Disorder-and-Schizophrenia-Accounted-for-Half-the-Market-Value-in-2010-159412.html



Summary

GBI Research, the leading business intelligence provider, has released its latest research “Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010”, which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.

GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, diabetic neuropathy, major depressive disorder (MDD),bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 indicating a CAGR of 4.7% The market is expected to witness a fluctuation in a view of patent expiries followed by generic erosion and possible launch of novel molecules.


Scope
- Data and analysis on the CNS disorder therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the CNS disorder therapeutics market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

Table of Contents :

1.1 List of Tables 8
1.2 List of Figures 12
2 CNS Disorder Therapeutic Market to 2017 - Introduction 15
2.1 GBI Research Report Guidance 15
3 CNS Disorder Therapeutic Market to 2017 - Global Market Overview 16
3.1 Introduction 16
3.2 Revenue 17
3.2.1 Generic Share 18
3.2.2 Annual Cost of Treatment 19
3.3 Top CNS Drug Products 20
3.3.1 Seroquel (IR/XR) (quetiapine fumarate) 20
3.3.2 Zyprexa (olanzapine) 20
3.3.3 Cymbalta (duloxetine Hcl) 21
3.3.4 Copaxone (glatiramer acetate) 21
3.3.5 Lyrica (pregabalin) 22
3.3.6 Abilify (aripiprazole) 22

3.3.7 Avonex (Interferon beta-1a) 23
3.3.8 Rebif (interferon beta-1a) 23
3.3.9 Effexor (venlafaxine) 23
3.3.10 Betaferon /Betaseron (Interferon beta-1b) 24
4 CNS Disorder Therapeutic Market to 2017 - Geographical Landscape 25
4.1 Revenue Analysis by Geography 25
4.2 The US 26
4.2.1 Revenue 26
4.2.2 Annual Cost of Treatment 27
4.3 Top Five Countries of Europe 28
4.3.1 Revenue 28
4.3.2 Annual Cost of Treatment 30
4.4 Japan 31
4.4.1 Revenue 31
4.4.2 Annual Cost of Treatment 32
5 CNS Disorder Therapeutic Market to 2017 - Therapeutic Landscape 33

For More Related Reports Please follow the link :
http://www.aarkstore.com/reports/Clinical-Trial-Recruitment-in-Central-Nervous-System-Disorders-Highest-Number-of-Patients-were-Recruited-for-Clinical-Trials-in-Schizophrenia-155023.html

http://www.aarkstore.com/reports/Central-Nervous-System-Tumors-Global-Clinical-Trial-Review-Q4-2010-76573.html

http://www.aarkstore.com/reports/Central-Nervous-System-Dementia-Therapy-Area-Pipeline-Report-32578.html

For all Related Reports Please follow the link:
http://www.aarkstore.com/search/viewresults.asp?search=Central Nervous System &PubId=&pagenum=1

About us:
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers. Our customers include more than 700 leading financial institutions, professional service firms, consulting, law and accounting firms and other corporations throughout the world.

For more information, please visit :

Contact: Marketing Team

Ph.No.918149852585

Email : enquiry@aarkstore.com/
URL: http://www.aarkstore.com/

central     Diso     nervous     system